Home> News> Read the interview with HARMONY Partners Jan Geissler, EUPATI/Leukanet and Matthias Gottwald, Bayer about the empowerment of patients
March 20, 2018 16:00 - x 00, 0 - 00:00
EUPATI built a much-needed programme for patient involvement in medicines research and development, and has been a game changer for patient empowerment in Europe, building a movement that will long outlive the project itself. In an interview with the IMI Programme Office, project coordinator Jan Geissler of the European Patients Forum, and Matthias Gottwald of Bayer explain how patients in Europe and beyond are benefitting from the work that was done.
Check the IMI project factsheet
Both Jan Geissler and Matthias Gottwald are partners of the HARMONY Alliance.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
